---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-084279"
form_type: "8-K"
ticker: "CUE"
cik: "0001645460"
company_name: "Cue Biopharma, Inc."
filed_at: "2025-06-10T23:59:59+00:00"
generated_at: "2026-05-19T15:47:11.514067+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cue Biopharma CFO resigns, elects Jill Broadfoot to board, increases authorized shares to 310M

## Summary
- CFO Kerri-Ann Millar resigns effective June 13, 2025; CEO Daniel Passeri will be interim principal financial and accounting officer.
- Jill Broadfoot appointed to board and Audit Committee chair; granted option to purchase 48,800 shares.
- Authorized shares of capital stock increased from 210M to 310M; common stock from 200M to 300M.
- Stockholders approved 2025 Stock Incentive Plan (13.85M for, 2.01M against); also elected all director nominees.

## SEC filing metadata
- accession: 0000950170-25-084279
- form_type: 8-K
- ticker: CUE
- cik: 0001645460
- company_name: Cue Biopharma, Inc.
- filed_at: 2025-06-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645460/000095017025084279/0000950170-25-084279-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645460/000095017025084279/cue-20250604.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-084279
- JSON: https://secwatch.observer/filing/0000950170-25-084279.json
- Plain text: https://secwatch.observer/filing/0000950170-25-084279.txt

## Key facts
- Executive change
  Jill Broadfoot was appointed as Director at Cue Biopharma, Inc..
  - Action: appointed
  - Role: Director
  source text: On June 4, 2025, Jill Broadfoot was appointed to the board of directors (the “Board”) of Cue Biopharma, Inc. (the “Company”), the Audit Committee of the Board, and the Corporate Governance and Nominating Committee of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645460/000095017025084279/0000950170-25-084279-index.htm
- Executive change
  Kerri-Ann Millar departed as Chief Financial Officer at Cue Biopharma, Inc..
  - Action: resigning
  - Role: Chief Financial Officer
  source text: On June 4, 2025, Kerri-Ann Millar notified the Company that she is resigning from her position as Chief Financial Officer, effective June 13, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645460/000095017025084279/0000950170-25-084279-index.htm
- Executive change
  Daniel R. Passeri changed role as principal financial and accounting officer at Cue Biopharma, Inc..
  - Action: will serve as
  - Role: principal financial and accounting officer
  source text: Effective June 13, 2025, Daniel R. Passeri, the Company’s Chief Executive Officer, will serve as the Company’s principal financial and accounting officer on an interim basis until a new principal financial and accounting officer is designated.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645460/000095017025084279/0000950170-25-084279-index.htm
- Governance Changes
  Cue Biopharma, Inc.: Increased authorized shares of capital stock from 210,000,000 to 310,000,000 and common stock from 200,000,000 to 300,000,000 (effective 2025-06-05).
  - Change: charter amendment
  - Effective: 2025-06-05
  source text: On June 5, 2025, the Company filed a Certificate of Amendment (the “Certificate of Amendment”) to its Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware effecting an amendment to increase the number of authorized shares of the Company’s capital stock from 210,000,000 to 310,000,000 and increase the number of authorized shares of the Company’s common stock from 200,000,000 to 300,000,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645460/000095017025084279/0000950170-25-084279-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.